Eli Lilly and Company (LLY) Stock
LLY Key Statistics
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
CEO: David A. Ricks. Company website
LLY — Frequently Asked Questions
What is the LLY stock price today?
Eli Lilly and Company (LLY) trades at $1,437.76, up 0.38% on the day, as of Nov 12, 2026 09:20 UTC.
What is Eli Lilly and Company's market cap?
Eli Lilly and Company has a market capitalisation of $1.35T, calculated from the live LLY share price and shares outstanding.
What is the P/E ratio of LLY?
LLY trades at a trailing P/E of 46.66, from earnings per share of $30.81 over the last twelve months.
How much revenue does Eli Lilly and Company make?
Eli Lilly and Company generated revenue of $86.46B over the trailing twelve months, which puts the stock at 15.64 times sales.
Does LLY pay a dividend?
Yes. Eli Lilly and Company pays a dividend yielding 0.58% on the current share price.
What is the 52-week range for LLY?
LLY has traded between $850.51 and $1,453.00 over the past 52 weeks, and the last price is 1.0% below that high.
Is Eli Lilly and Company profitable?
Yes. Eli Lilly and Company keeps 31.90% of revenue as net income over the trailing twelve months.
What is the analyst price target for LLY?
Wall Street analysts rate LLY Buy, with an average price target of $1,445.12, 0.5% above the current price.
What sector is Eli Lilly and Company in?
Eli Lilly and Company is classified under the Healthcare sector and the Drug Manufacturers - General industry, and is domiciled in US.
Who is the CEO of Eli Lilly and Company?
David A. Ricks is the chief executive of Eli Lilly and Company, which employs 50,000 people.
Where can I track LLY in real time?
QFI Terminal shows LLY with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See LLY live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open LLY in Terminal See plans